A pharma exec gets $100M to chase a cancer-fighting idea uncovered in a 2017 Novartis study
Harlan Weisman, a longtime pharma and biotech executive, was starting up his latest project in the summer of 2017 when he caught wind of a major study coming out of Novartis. A 10,000-person study published in The New England Journal of Medicine showed that a Novartis antibody that blocked one of the key pathways of inflammation, interleukin 1 beta, significantly reduced the odds of major cardiovascular events like heart attack and stroke in high-risk patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.